To exclude the possibility that another factor is affecting the lifetime GAF scores, we adjusted the analyses for mental diseases other than depression or anxiety disorders (e.g., substance use schizoaffective, psychotic, and bipolar disorders): the effect of CYP2C19 metabolizer status on lifetime GAF score remained significant (ß = 2.9, 95% CI: 0.84–5.0, p = 0.006, data not shown). This evidence concerns the gene CYP2C19 and major depressive disorder.